Search

Your search keyword '"Nam, Seung Hyun"' showing total 32 results
Start Over Author "Nam, Seung Hyun" Search Limiters Peer Reviewed
32 results on '"Nam, Seung Hyun"'

2. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Author

Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool-Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera-Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Salem, Ayman Abd Elhamid Ebrahim Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann-Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Cuneo, Carlos Alberto, Diaz, Carlos Jerjes Sanchez, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Zaidman, Cesar Javier, Lunn, Charles, Wu, Chau-Chung, Toh, Cheng Hock, Chiang, Chern-En, Elisa, Chevrier, Hsia, Chien-Hsun, Huang, Chien-Lung, Kwok, Chi-Hang Kevin, Wu, Chih-Cheng, Huang, Chi-Hung, Ward, Chris, Opitz, Christian, Jeanneret-Gris, Christina, Ha, Chung Yin, Huang, Chun-Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, David - Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs-Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz, Enrique Diaz, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala-Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia-Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye-Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Esperón, Guillermo Antonio Llamas, Jean-Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans-Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, Bounameaux, Henri, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho-Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik-Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M., Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer-Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen-Yuan, Shih, Jhih-Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Souto, Joan Carlos, Correa, João Antônio, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Paez, Jorge Guillermo Chavez, Nielsen, Jørn, Filho, Jose Dalmo Araujo, Saraiva, Jose, Peromingo, Jose Antonio Diaz, Lara, Jose Gomez, Fedele, Jose Luis, Surinach, Jose Maria, Chacko, Joseph, Muntaner, Juan Antonio, Benitez, Juan Carlos Álvarez, Abril, Juan Moreno Hoyos, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou-Gi, Vandenbosch, Kristel, Chang, Kuan-Cheng, Chiu, Kuan-Ming, Jean-Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo-Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Schiavi, Lilia Beatriz, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, López, Luciano Eduardo, Ria, Luigi, Blasco, Luis Manuel Hernandez, Guzman, Luis Alberto, Cervera, Luis Flota, Isabelle, Mahe, Bosch, Manuel Monreal, de los Rios Ibarra, Manuel, Fernandez, Manuel Núñez, Carrier, Marc, Barrionuevo, Marcelo Raul, Gamba, Marco Antonio Alcocer, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool-Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El-Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon-Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Flores, Oscar Nandayapa, Gur, Ozcan, Oto, Oztekin, Marchena, Pablo Javier, Angchaisuksiri, Pantep, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, de Leon, Raul Franco Diaz, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan-Keim, Reinhold, Otero, Remedios, Murena-Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Schellong, Sebastian, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung-Hyun, Marie-Antoinette, Sevestre-Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Goto, Shinya, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean-Léopold, Siwe-Nana, Wongkhantee, Somchai, Bang, Soo-Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel-Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting-Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Ageno, Walter, Pharr, Walter, Jiang, Weihong, Lin, Wei-Hsiang, Zhang, Weihua, Tseng, Wei-Kung, Lai, Wen-Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won Il, Kim, Yang-Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung-Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, Yang, Zhongqi, Turpie, Alexander G.G., Farjat, Alfredo E., Haas, Sylvia, Weitz, Jeffrey I., Goldhaber, Samuel Z., Kayani, Gloria, Lopes, Renato D., Tse, Eric, Muntaner, Juan, Prandoni, Paolo, Maheshwari, Uma, and Kakkar, Ajay K.

Published
2023
Full Text
View/download PDF

3. The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients

Author

Park, Hyunkyung, Kang, Sungbong, Kim, Inho, Kim, Sangsoo, Kim, Hyeong-Joon, Shin, Dong-Yeop, Kim, Dae-Young, Lee, Kyoo-Hyung, Ahn, Jae-Sook, Sohn, Sang-Kyun, Lee, Jeong-Ok, Cheong, June-Won, Kim, Kyoung Ha, Kim, Hoon-Gu, Kim, Hawk, Lee, Yoo Jin, Nam, Seung-Hyun, Do, Young Rok, Park, Sang-Gon, Park, Seong Kyu, Song, Hun Ho, Jung, Chul Won, and Park, Seonyang

Published
2022
Full Text
View/download PDF

4. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients

Author

Park, Hyunkyung, Kim, Inho, Kim, Hyeong-Joon, Shin, Dong-Yeop, Lee, Sung-Yeoun, Kwon, Oh-Hyung, Kim, Dae-Young, Lee, Kyoo-Hyung, Ahn, Jae-Sook, Park, Jinny, Sohn, Sang-Kyun, Lee, Jeong-Ok, Cheong, June-Won, Kim, Kyoung Ha, Kim, Hoon-Gu, Kim, Hawk, Lee, Yoo Jin, Nam, Seung-Hyun, Do, Young Rok, Park, Sang-Gon, Park, Seong Kyu, Bae, Sung Hwa, Song, Hun Ho, Oh, Doyeun, Jung, Chul Won, and Park, Seonyang

Published
2021
Full Text
View/download PDF

7. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Author

Haas, Sylvia, Ageno, Walter, Weitz, Jeffrey I., Goldhaber, Samuel Z., Turpie, Alexander G.G., Goto, Shinya, Angchaisuksiri, Pantep, Dalsgaard Nielsen, Joern, Kayani, Gloria, Zaghdoun, Audrey, Farjat, Alfredo E., Schellong, Sebastian, Bounameaux, Henri, Mantovani, Lorenzo G., Prandoni, Paolo, Kakkar, Ajay K., Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool‐Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera‐Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Ebrahim, Ayman Abd Elhamid, Salem, Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann‐Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Alberto Cuneo, Carlos, Sanchez Diaz, Carlos Jerjes, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Javier Zaidman, Cesar, Lunn, Charles, Wu, Chau‐Chung, Toh, Cheng Hock, Chiang, Chern‐En, Elisa, Chevrier, Hsia, Chien‐Hsun, Huang, Chien‐Lung, Kwok, Chi‐Hang Kevin, Wu, Chih‐Cheng, Huang, Chi‐Hung, Ward, Chris, Opitz, Christian, Jeanneret‐Gris, Christina, Ha, Chung Yin, Huang, Chun‐Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs‐Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz Diaz, Enrique, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala‐Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia‐Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye‐Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Llamas Esperón, Guillermo Antonio, Jean‐Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans‐Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho‐Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik‐Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M, Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer‐Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen‐Yuan, Shih, Jhih‐Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Carlos Souto, Joan, Antônio Correa, João, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Chavez Paez, Jorge Guillermo, Araujo Filho, Jose Dalmo, Saraiva, Jose, Diaz Peromingo, Jose Antonio, Gomez Lara, Jose, Luis Fedele, Jose, Maria Surinach, Jose, Chacko, Joseph, Antonio Muntaner, Juan, Álvarez Benitez, Juan Carlos, Hoyos Abril, Juan Moreno, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou‐Gi, Vandenbosch, Kristel, Chang, Kuan‐Cheng, Chiu, Kuan‐Ming, Jean‐Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo‐Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Beatriz Schiavi, Lilia, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, Eduardo López, Luciano, Ria, Luigi, Hernandez Blasco, Luis Manuel, Guzman, Luis Alberto, Flota Cervera, Luis, Isabelle, Mahe, Monreal Bosch, Manuel, de los Rios Ibarra, Manuel, Núñez Fernandez, Manuel, Carrier, Marc, Raul Barrionuevo, Marcelo, Alcocer Gamba, Marco Antonio, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool‐Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El‐Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon‐Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Nandayapa Flores, Oscar, Gur, Ozcan, Oto, Oztekin, Javier Marchena, Pablo, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, Diaz de Leon, Raul Franco, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan‐Keim, Reinhold, Otero, Remedios, Murena‐Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung‐Hyun, Marie‐Antoinette, Sevestre‐Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean‐Léopold, Siwe‐Nana, Wongkhantee, Somchai, Bang, Soo‐Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel‐Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting‐Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Pharr, Walter, Jiang, Weihong, Lin, Wei‐Hsiang, Zhang, Weihua, Tseng, Wei‐Kung, Lai, Wen‐Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won II, Kim, Yang‐Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung‐Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, and Yang, Zhongqi

Published
2019
Full Text
View/download PDF

8. Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.

Author

Jang, Yoon Jung, Lim, Sang Moo, Lee, Inki, Byun, Byung Hyun, Lim, Ilhan, Kim, Byung Il, Choi, Chang Woon, Lee, Seung‐Sook, Suh, Cheolwon, Yoon, Dok Hyun, Kim, Inho, Nam, Seung‐Hyun, Lee, Mark Hong, Won, Jong Ho, Kong, Jee Hyun, Jeong, Seong Hyun, Oh, Suk Joong, Park, Keon Woo, Han, Jae Joon, and Song, Moo‐Kon

Subjects
RADIOIMMUNOTHERAPY, FOLLICULAR lymphoma, MANTLE cell lymphoma, POSITRON emission tomography, ADVERSE health care events, COMPUTED tomography
Abstract

Aim: This study aimed to evaluate the safety and efficacy of 131I‐rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma. Methods: Twenty‐four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of 131I‐rituximab. Contrast‐enhanced 18F‐fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response. Results: This study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), 131I‐rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression‐free and overall survival was 5.9 and 37.9 months, respectively. During the follow‐up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment‐related adverse events, hematologic toxicities were common, and grade 3–4 thrombocytopenia and neutropenia were reported in 66.6% of cases. Conclusion: 131I‐rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Raman tensor studies on defective non-van der Waals Bi2O2Se.

Author

Kim, Un Jeong, Nam, Seung Hyun, Kim, Seok In, Han, Yoojoong, Yoon, Jeechan, Gutiérrez, Humberto R., Cheon, Miyeon, Kim, Gun Cheol, Park, Yeonsang, Lee, Moonsang, Hahm, Myung Gwan, and Son, Hyungbin

Subjects
*BACKSCATTERING, *CRYSTALS
Abstract

The Raman tensors of the three modes at ∼55, ∼80, and ∼160 cm−1 for the non-van der Waals layered material Bi2O2Se, which were assigned to Eu, Eg, and A1g, respectively, were experimentally investigated. Two modes at ∼55 and ∼80 cm−1, which were not observable in perfect crystal Bi2O2Se in the backscattering configuration, owing to the Raman selection rule, were activated by defects. These two modes exhibit strong polarization dependence at line defects and the excitation energy; thus, their Raman polarizability tensors exhibit strong dependence on the defect morphology and geometric characteristics of Bi2O2Se. The results of this study confirm that the Raman tensors of nanocrystalline structures can be modulated by defects. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. A Tighter Converse for the Locally Differentially Private Discrete Distribution Estimation Under the One-bit Communication Constraint.

Author

Nam, Seung-Hyun and Lee, Si-Hyeon

Subjects
DISTRIBUTION (Probability theory), FISHER information, PRIVACY
Abstract

We consider a discrete distribution estimation problem under the local differential privacy and the one-bit communication constraints. A fundamental privacy-utility tradeoff in this problem is formulated as the minimax squared loss. We show a tighter lower bound on the minimax squared loss, which has exactly the same form with the upper bound by the recursive Hadamard response by Chen et al. up to a constant factor of 4 for arbitrary LDP constraint and arbitrary finite data space. To derive the lower bound, we modify the van Trees inequality to involve a symmetrized Fisher information, which is invariant under the choice of the coordinate system on the probability simplex. We further characterize the maximum of the symmetrized Fisher information by considering the joint effect of the privacy and the communication constraints. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Secrecy Capacity of a Gaussian Wiretap Channel With ADCs is Always Positive.

Author

Nam, Seung-Hyun and Lee, Si-Hyeon

Subjects
*GAUSSIAN channels, *ANALOG-to-digital converters, *PHYSICAL layer security
Abstract

We consider a complex Gaussian wiretap channel with finite-resolution analog-to-digital converters (ADCs) at both the legitimate receiver and the eavesdropper. For this channel, we show that a positive secrecy rate is always achievable as long as the channel gains at the legitimate receiver and at the eavesdropper are different, regardless of the quantization levels of the ADCs. For the achievability, we first consider the case of the one-bit ADCs at the legitimate receiver and apply a binary input distribution where the two input points have the same phase when the channel gain at the legitimate receiver is less than that at the eavesdropper, and otherwise the opposite phase. Then the result is generalized for the case of arbitrary finite-resolution ADCs at the legitimate receiver by translating the input distribution appropriately. We also provide numerical lower bounds on the achievable secrecy rates, and analyze the tendency of the secrecy rates according to the channel difference, the power constraint, and the quantization levels for some cases. For the special case of the real Gaussian wiretap channel with one-bit ADCs at both the legitimate receiver and the eavesdropper, we show that our choice of phase does not lose any optimality for the Wyner code. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. High-throughput block-matching VLSI architecture with low memory bandwidth

Author

Nam, Seung Hyun and Lee, Moon Key

Subjects
Very-large-scale integration -- Design and construction, Image processing -- Equipment and supplies, Business, Computers and office automation industries, Electronics, Electronics and electrical industries
Abstract

A full-search block-matching architecture which features high throughput, low data input lines, and low memory bandwidth is proposed. It reduces memory I/O requirements by the maximum reuse of search data using on-chip memory. It also promises a high throughput rate by the continuous calculation of all block distortions in a search area using two search data input flows without processing any invalid block distortion, and by the continuous process of the neighbored reference blocks removing the initialization period between blocks. The processor for -16/+15 search ranges, implemented in the total 220k gates using 0.6 [[micro]meter] triple-metal CMOS technology, can operate at a 66 MHz clock rate, and therefore is capable of encoding H.263(4CIF), MPEG2(MP@ML), and other multimedia applications.

Published
1998

24. Flexible VLSI architecture of motion estimator for video image compression

Author

Nam, Seung Hyun and Lee, Moon Key

Subjects
Data compression -- Analysis, Arrays (Data structures) -- Usage, Very-large-scale integration -- Research, Business, Computers and office automation industries, Electronics, Electronics and electrical industries
Abstract

A linear array architecture for full-search block matching algorithm is proposed. It is suitable for low bit-rate video applications with a single chip realization. It uses a parallel algorithm based on the idea of partial result accumulation. Combining a serial data input with registers for a line of search window pixels and operating on them in parallel, the partial results of the candidate block distortions are obtained for all horizontal search positions, which are successively accumulated into cyclic storage buffer. Based on this scheme, a flexible architecture can be designed for motion vector estimation of different search ranges and block sizes.

Published
1996

26. The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma.

Author

Lee, Gyeong-Won, Park, Sung Woo, Go, Se-Il, Kim, Hoon-Gu, Kim, Min Kyoung, Min, Chang-Ki, Kwak, Jae-Yong, Bae, Sang-Byung, Yoon, Sung-Soo, Lee, Je-Jung, Kim, Ki Hwan, Nam, Seung-Hyun, Mun, Yeung-Chul, Kim, Hyo Jung, Bae, Sung Hwa, Shin, Ho-Jin, Lee, Jung-Hee, Park, Joon Seong, Jeong, Seong Hyun, and Lee, Mark Hong

Subjects
NEUTROPHILS, LYMPHOCYTES, MULTIPLE myeloma, BORTEZOMIB, STEM cell transplantation
Abstract

Background: The neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic marker in solid and hematological cancers. While the derived NLR (dNLR) was shown to be non-inferior to the NLR in large cohorts of patients with different cancer types, it has not been validated as a prognostic marker for multiple myeloma (MM) to date. Methods: Between May 22, 2011 and May 29, 2014, 176 patients with MM from 38 centers who were ineligible for autologous stem cell transplantation were analyzed. The dNLR was calculated using complete blood count differential data. The optimal dNLR cut-off value according to receiver operating characteristic analysis of overall survival (OS) was 1.51. All patients were treated with melphalan and prednisone combined with bortezomib. Results: The complete response rate was lower in the high dNLR group compared to the low dNLR group (7 vs. 26.1%, respectively; p = 0.0148); the corresponding 2-year OS rates were 72.2 and 84.7%, respectively (p = 0.0354). A high dNLR was an independent poor prognostic factor for OS (hazard ratio 2.217, 95% CI 1.015–4.842; p = 0.0458). Conclusion: The dNLR is a readily available and cheaply obtained parameter in clinical studies, and shows considerable potential as a new prognostic marker for transplantation-ineligible patients with MM. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

27. Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer.

Author

Kwon, Jung Hye, Nam, Seung-Hyun, Koh, Sujin, Hong, Young Seon, Lee, Kyung Hee, Shin, Sang-Won, Hui, David, Park, Kyun Woo, Yoon, So Young, Won, Ji Yun, Chisholm, Gary, and Bruera, Eduardo

Subjects
*SYMPTOMS, *KOREANS, *CANCER patients, *QUESTIONNAIRES, *PILOT projects, *CRONBACH'S alpha, *DISEASES
Abstract

Abstract: Context: The Edmonton Symptom Assessment System (ESAS) is a brief, widely adopted, multidimensional questionnaire to evaluate patient-reported symptoms. Objectives: To develop a Korean version of the ESAS (K-ESAS) and to perform a psychometric analysis in Korean patients with advanced cancer. Methods: We tested the K-ESAS in two pilot studies with 15 patients each. We assessed internal consistency, test-retest reliability, and concurrent validity in 163 Korean patients, who completed the K-ESAS along with the Korean versions of the M. D. Anderson Symptom Inventory (K-MDASI) and the Hospital Anxiety and Depression Scale (K-HADS) twice. A total of 38 patients completed the questionnaires again seven days later to assess responsiveness. Results: The K-ESAS scores had good internal consistency, with a Cronbach's alpha coefficient of 0.88, indicating that no questions had undue influence on the score. Pearson correlation coefficients for K-ESAS symptom scores between baseline and after two to four hours ranged from 0.72 (95% CI 0.64–0.79) to 0.87 (95% CI 0.82–0.90), indicating strong test-retest reliability. For concurrent validity, Pearson correlation coefficients between K-ESAS symptom scores and corresponding K-MDASI symptom scores ranged from 0.70 (95% CI 0.62–0.77) to 0.83 (95% CI 0.77–0.87), indicating good concurrent validity. For the K-HADS, concurrent validity was good for anxiety (r =0.73, 95% CI 0.65–0.79) but moderate for depression (r =0.4, 95% CI 0.26–0.52). For responsiveness, changes in K-ESAS scores after seven days were moderately correlated with changes in K-MDASI scores but weakly correlated with changes in K-HADS scores. Conclusion: The K-ESAS is a valid and reliable tool for measuring multidimensional symptoms in Korean patients with cancer. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

28. Repeated radioimmunotherapy with I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma.

Author

Kang, Hye, Lee, Seung-Sook, Byun, Byung, Kim, Kyeong, Lim, Ilhan, Choi, Chang, Suh, Cheolwon, Kim, Won, Nam, Seung-Hyun, Lee, Soon, Eom, Hyeon, Shin, Dong-Yeop, and Lim, Sang

Subjects
CANCER radioimmunotherapy, RITUXIMAB, CANCER relapse, B cells, LYMPHOMA treatment, DRUG dosage, POSITRON emission tomography, THROMBOCYTOPENIA
Abstract

Purpose: A single treatment of I-rituximab in patients with B cell non-Hodgkin lymphoma (NHL) showed a modest rate of response (29 %) in a relatively short duration (median 2.9 months). On the basis of this result, we investigated whether repeated treatment with I-rituximab could improve the response. Patients and methods: Thirty-one patients with relapsed or refractory B cell NHL received unlabeled rituximab (70 mg) immediately prior to the administration of a therapeutic dose of I-rituximab. The tumor response was evaluated 1 month later by contrast-enhanced F-fluorodeoxyglucose positron emission tomography/computed tomography. Radioimmunotherapy (RIT) was repeated at 4-week intervals. Results: A total of 87 cycles of RIT were administered. Repeated RIT yielded twofold increases in response rate (68 %) and in median response duration (8.6 months). This protocol also induced a favorable response in patients with an aggressive histology compared to that induced by a single treatment (50 vs. 9 %, respectively, p = 0.063). The toxicities were principally hematologic with grade 4 thrombocytopenia occurring in 12 % and neutropenia occurring in 17 % of the 85 assessable cycles. Conclusions: Compared to a single treatment, repeated RIT with I-rituximab increased the response rate and duration for patients with relapsed or refractory B cell NHL, including those with an aggressive histology. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

32. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Author

Kim, Ji-Won, Min, Chang-Ki, Mun, Yeung-Chul, Park, Yong, Kim, Byung Soo, Nam, Seung-Hyun, Koh, Youngil, Kwon, Ji-Hyun, Choe, Pyoeng Gyun, Park, Wan Beom, and Kim, Inho

Subjects
*VARICELLA-zoster virus diseases, *IMMUNITY, *MULTIPLE myeloma, *BORTEZOMIB, *THALIDOMIDE, *CANCER chemotherapy, *PATIENTS
Abstract

Background The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM). Objectives This study aimed to elucidate the effect of chemotherapy with or without bortezomib in MM patients on their herpes zoster incidence and varicella zoster virus (VZV)-specific cell-mediated immunity (CMI). Study design Peripheral blood mononuclear cells were collected at baseline and after 1 month of bortezomib-based or thalidomide-based chemotherapy and then analyzed using VZV-specific interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay. The clinical data from these patients were analyzed in relation to the ELISPOT results. Results Of 58 patients analyzed, 39 patients received bortezomib and the other 19 patients, thalidomide. Among them, 5 patients developed herpes zoster during chemotherapy; all 5 were being treated with the bortezomib-based regimen and were not receiving prophylactic anti-viral agents. The median onset of herpes zoster was 32 days (range, 15–95 days) from the initiation of chemotherapy. Among patients who received bortezomib therapy, acyclovir prophylaxis significantly reduced the risk for herpes zoster (100-day cumulative incidence, 0% vs. 49.5%; p < 0.001). Spot-forming cell (SFC) counts in the IFN-γ ELISPOT assay decreased from baseline after bortezomib ( p = 0.011) or thalidomide ( p = 0.096) treatment. Patients with baseline SFCs greater than 20/10 6 mononuclear cells exhibited significantly higher incidence of herpes zoster (100-day cumulative incidence, 34.8% vs. 0%; p = 0.040). Conclusions Bortezomib treatment significantly reduced VZV-specific CMI, and high baseline SFC counts in patients receiving this treatment without acyclovir prophylaxis were associated with a significantly increased risk for herpes zoster. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results